Abstract
Background
Neuropathy is a common adverse effect of chemotherapy. However, the both the prevalence and the burden of this adverse effect have been poorly documented. The aim of the study was to assess the prevalence and discomfort caused by neuropathic symptoms in relation to other adverse effects of chemotherapy.
Patients and methods
Between January 2002 and June 2004, we screened 448 patients who were treated with vinca alkaloids, taxanes or platina derivatives, using a simple questionnaire of neuropathic symptoms. The response rate was 75%. Neuropathic symptoms were reported by 258 respondents (76%), of whom 152 patients were eligible for the final analyses. The severity of neuropathy was scored using the National Cancer Institute Common Toxicity Criteria.
Results
At the screening visit, 90 patients (59%) still reported neuropathic symptoms. Tingling (71%), numbness (58%), impaired sensory function (46%) and pain in hands and feet (40%) were the most common symptoms. The median intensity of neuropathic symptoms was 28/100 on the visual analogue scale. Grade 1 sensory neuropathy was found in 19 out of 90 patients (21%), grade 2 in 38 (42%) and grade 3 in 33 (37%) patients. Grade 1 motor neuropathy was found in 28 (31%), grade 2 in 14 (16%) and grade 3 in one patient (1%). Grade 4 sensory or motor neuropathy was not seen. In the whole cohort of 152 patients, fatigue (66%), mucositis (61%) and neuropathic symptoms (59%) were the most commonly reported symptoms. Every third patient (37%) with neuropathic symptoms ranked them as the most troublesome symptom.
Discussion
Neuropathy is a common and troublesome adverse effect of chemotherapy, even though the intensity of the symptoms is mild. Thus, the intensity and inconvenience does not correlate to each other.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ocean AJ, Vahdat LT (2004) Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 12:619–625
Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249:9–17
Winton T, Livingston R, Johnson D et al (2005) Vinorelbine plus cisplatin vs. observation in resected non small-cell lung cancer. N Engl J Med 352:2589–2597
Albers J,Chaudhry V, Cavaletti G, Donehower R (2007) Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev (1):CD005228. Review
Attal N, Cruccu G, Haanpää M, Hansson P, Jensen TS, Nurmikko T et al (2006) EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13:1153–1169
Hammack JE, Michalak JC, Loprinzi CL et al (2002) Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 98:195–203
Kautio A, Haanpää M, Saarto T, Kalso E (2008) Amitriptylin in the treatment of chemotherapy incuded neuropathic symptoms. J Pain Symptom Manage 35:31–39
Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA et al (2007) Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy. Cancer 110:21110–21118
Rao RD, Flynn PJ, Sloan JA, Wong GY, Novotny P, Johnson DB et al (2008) Efficay of lamotrigine in the management of chemotherapy-induced peripheral neuropathy. Cancer 112:2802–2808
von Delius S, Eckel F, Wagenpfeil S, Mayr M, Stock K, Kullmann F et al (2007) Carbamazepine for prevention of oxaliplatin related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study. Invest New Drugs 25:173–180
Pace A, Bove L, Nisticò C, Ranuzzi M, Innocenti P, Pietrangeli A et al (1996) Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psych 61:409–411
Shimozuma K, Ohashi Y, Takeuchi A et al (2009) Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase II randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer 17(12):1483–1491
Postma TJ, Heimans JJ (2000) Grading chemotherapy-induced peripheral neuropathy. Ann Oncol 11:509–513
Chaudhry V, Chaudhry M, Crawford TO, Simmons-O'Brien E, Griffin JW (2003) Toxic neuropathy in patients with pre-existing neuropathy. Neurology 60:337–340
Sindrup SH, Gram LF, Brøsen K, Eshøj O, Mogensen EF (1990) The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 42(2):135–144
Cata JP, Weng HR, Burton AW, Villareal H, Giralt S, Dougherty PM (2007) Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 8:296–306
Forsyth PA, Balmaceda C, Peterson K, Seidman AD, Brasher P (1997) DeAngelis LM.Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol 35:47–53
Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, Parma G, Lissoni A, Fei F, Cundari S, Zanna C (2003) Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology 61:1297–1300
Markman M (2006) Chemotherapy-induced peripheral neuropathy: underreported and underappreciated. Curr Pain Rep 3:154–157
Conflict of interest
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kautio, AL., Haanpää, M., Kautiainen, H. et al. Burden of chemotherapy-induced neuropathy—a cross-sectional study. Support Care Cancer 19, 1991–1996 (2011). https://doi.org/10.1007/s00520-010-1043-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-010-1043-2